one
common
caus
ill
human
respiratori
tract
infect
caus
bacteri
viral
fungal
pathogen
inhal
antiinfect
drug
crucial
prophylaxi
treatment
respiratori
tract
infect
benefit
antiinfect
drug
deliveri
via
inhal
afford
deliveri
suffici
therapeut
dosag
directli
primari
site
infect
minim
risk
system
toxic
avoid
potenti
suboptim
pharmacokineticspharmacodynam
associ
system
drug
exposur
review
provid
uptod
treatis
approv
novel
development
inhal
antiinfect
agent
particular
attent
effect
strategi
use
pulmonari
pharmacokinet
properti
safeti
one
common
caus
ill
human
popul
far
aris
respiratori
tract
infect
ventilatorassoci
pneumonia
frequent
nosocomi
infect
intens
care
unit
due
million
physician
visit
hospit
lost
work
hour
econom
cost
respiratori
infect
run
hundr
billion
year
influenza
epidem
alon
usa
total
annual
econom
burden
use
project
statist
life
valu
approxim
billion
import
human
pathogen
organ
respons
respiratori
infect
includ
bacteria
eg
pseudomona
aeruginosa
fungi
eg
aspergillu
spp
virus
eg
respiratori
syncyti
viru
influenza
viru
high
cumul
burden
morbid
econom
loss
inhal
antiinfect
drug
play
pivot
role
prophylaxi
treatment
common
respiratori
infect
effect
treatment
involv
aerosol
drug
administr
deliv
antiinfect
agent
directli
respiratori
tract
therebi
achiev
drug
concentr
suffici
erad
pathogen
organ
site
infect
importantli
aerosol
administr
greatli
reduc
potenti
toxic
associ
system
exposur
primari
mode
aerosol
pulmonari
deliveri
antiinfect
agent
via
nebul
use
jet
system
ultrason
system
system
use
vibrat
meshapertur
plate
although
aerosol
deliveri
mani
advantag
pauciti
data
safeti
efficaci
pulmonari
pharmacokinet
antiinfect
administ
via
rout
moreov
drug
specif
design
formul
pulmonari
deliveri
develop
futur
advanc
depend
upon
develop
novel
deliveri
devic
formul
optim
pulmonari
pharmacokineticspharmacodynam
pkpd
drug
broadspectrum
inhal
agent
importantli
potent
inhal
antiinfect
agent
need
possess
high
therapeut
index
decreas
high
rate
clinic
failur
emerg
resist
paper
provid
uptod
overview
current
approv
inhal
antiinfect
drug
particular
attent
effect
strategi
use
key
find
clinic
studi
safeti
pulmonari
pharmacokinet
novel
inhal
compound
formul
develop
pipelin
also
review
complement
written
materi
reader
refer
fig
chemic
structur
antiinfect
agent
discuss
review
addit
tabl
summar
clinic
properti
indic
inhal
antiinfect
agent
devic
formul
design
inhal
antibiot
therapi
review
anoth
articl
issu
henc
discuss
detail
inhal
antibiot
use
approv
indic
well
offlabel
use
current
least
three
antibiot
approv
indic
chronic
suppress
treatment
infect
caus
p
aeruginosa
patient
cystic
fibrosi
cf
colon
p
aeruginosa
occur
high
percentag
adult
patient
cf
caus
inflamm
airway
lead
high
morbid
mortal
three
inhal
antipseudomon
antibiot
tobramycin
aminoglycosid
aztreonam
monobactam
colistin
also
known
polymyxin
e
fig
offlabel
use
includ
indic
ventilatorassoci
pneumonia
vap
noncf
bronchiectasi
pulmonari
exacerb
patient
section
mainli
cover
inhal
antibiot
approv
manag
patient
cf
chronic
infect
p
aeruginosa
advantag
inhal
antibiot
formul
higher
concentr
respiratori
tract
rapidli
achiev
minim
system
exposur
may
lead
advers
effect
prior
develop
inhal
formul
antibiot
extemporan
prepar
intraven
form
aerosol
howev
ideal
safeti
efficaci
patient
well
establish
moreov
bronchospasm
provok
due
presenc
preserv
intraven
product
wherea
current
inhal
antibiot
formul
contain
preserv
first
avail
aerosol
antibiot
approv
food
drug
administr
fda
tobramycin
fig
antibiot
belong
aminoglycosid
class
tobramycin
inhibit
protein
synthesi
irrevers
bind
ribosom
subunit
also
caus
damag
bacteri
outer
membran
tobramycin
mainli
indic
treatment
seriou
infect
caus
gramneg
bacteria
often
reserv
seriou
infect
resist
antibacteri
sentri
antimicrobi
surveil
program
incid
aminoglycosid
resist
clinic
isol
p
aeruginosa
tobramycin
europ
unit
state
tobramycin
inhal
solut
ti
first
introduc
doubleblind
random
placebocontrol
clinic
studi
demonstr
inhal
tobramycin
significantli
improv
lung
function
reduc
exacerb
risk
hospit
cf
patient
chronic
infect
p
aeruginosa
current
multipl
formul
tobramycin
avail
administr
inhal
two
nebul
solut
ml
ml
capsulebas
dri
powder
inhal
object
increas
concentr
dose
solut
reduc
time
administr
cf
patient
solut
contain
ampoul
use
pari
plu
reusabl
nebul
devilbiss
air
compressor
recommend
dose
adult
children
year
old
mg
twice
daili
day
stop
day
repeat
cycl
nebul
procedur
usual
take
min
major
advers
effect
tabl
report
nebul
tobramycin
includ
bronchospasm
voic
alter
transient
tinnitu
without
hear
loss
tobramycin
solut
inhal
mg
ml
twice
day
shown
give
mean
peak
sputum
concentr
min
inhal
first
last
dose
studi
period
mean
serum
concentr
accumul
tobramycin
sputum
serum
cours
studi
interestingli
estim
system
bioavail
nebul
henc
nebul
tobramycin
substanti
increas
therapeut
ratio
parenter
administr
latter
caus
nephrotox
ototox
adult
infant
patient
recent
studi
carri
retrospect
analysi
cystic
fibrosi
foundat
patient
registri
cffpr
report
regress
adjust
use
tobramycin
inhal
solut
associ
reduct
odd
subsequ
year
mortal
patient
cf
anoth
commerci
product
tobramycin
inhal
solut
avail
mg
ml
prepar
inhal
min
use
pari
plu
pari
sprint
nebul
suitabl
compressor
treatment
regimen
cycl
ie
mg
twice
day
day
stop
day
averag
sputum
concentr
tobramycin
min
inhal
first
dose
mg
week
treatment
one
hour
inhal
singl
dose
mg
cf
patient
median
serum
concentr
tobramycin
treatment
time
point
recent
studi
examin
differ
pharmacokinet
toler
profil
tobramycin
solut
mg
ml
administ
pari
rapid
compar
pari
plu
nebul
maximum
sputum
concentr
tobramycin
eflow
higher
plu
day
furthermor
administr
time
reduc
min
min
import
order
address
poor
complianc
total
treatment
burden
term
treatment
burden
use
nebul
requir
disassembl
clean
everi
dose
long
administr
time
may
affect
patient
complianc
strategi
overcom
nonadher
need
address
recent
dri
powder
inhal
dpi
form
tobramycin
develop
approv
dpi
conveni
devic
much
smaller
portabl
also
take
less
time
use
requir
special
clean
howev
unlik
nebul
inspiratori
effort
patient
gener
affect
deliveri
dose
dpi
tobi
develop
use
technolog
tobramycin
dri
powder
place
capsul
mg
tobramycin
per
capsul
use
via
tobi
inhal
devic
recommend
dose
patient
age
year
older
capsul
mg
tobramycin
twice
day
day
stop
day
follow
new
treatment
cycl
studi
cf
patient
show
similar
pharmacokinet
observ
mg
tobramycin
inhal
solut
use
pari
plu
nebul
capsul
tobramycin
dpi
total
mg
use
sputum
formul
achiev
maximum
concentr
c
max
h
inhal
dpi
formul
deliv
much
effici
nebul
inhal
solut
phaseiii
studi
show
compar
placebo
group
subject
tobramycin
dpi
group
experienc
statist
signific
improv
mean
forc
expiratori
volum
fev
end
first
treatment
cycl
improv
fev
retain
day
treatment
also
decreas
densiti
p
aeruginosa
cell
sputum
fewer
hospit
relat
respiratori
event
use
fewer
concomit
antipseudomon
antibiot
peer
receiv
placebo
even
first
treatment
period
anoth
recent
phaseiii
studi
demonstr
term
efficaci
tobramycin
inhal
powder
inferior
tobramycin
inhal
solut
respect
lung
function
benefit
safeti
profil
formul
also
similar
howev
higher
incid
cough
report
patient
receiv
tobramycin
inhal
powder
compar
nebul
tobramycin
compar
term
intens
cough
event
mild
moder
group
dysphonia
dysgeusia
also
occur
higher
frequenc
tobramycin
inhal
powder
group
compar
nebul
tobramycin
group
report
antibacteri
activ
tobramycin
antagon
cf
sputum
due
bind
sputum
compon
mucin
dna
presenc
sputum
rel
high
concentr
tobramycin
need
reduc
densiti
p
aeruginosa
tobramycin
concentr
higher
minimum
inhibitori
concentr
mic
requir
produc
reason
bactericid
effect
pharmacokinet
data
trial
demonstr
larg
variabl
sputum
concentr
tobramycin
nonetheless
subject
sputum
concentr
exceed
mic
note
whether
concentr
exposur
sputum
epithelium
line
fluid
elf
predict
pkpd
index
necessit
examin
besid
use
chronic
suppress
therapi
also
studi
tobramycin
earli
bacteri
erad
howev
well
design
studi
adult
popul
studi
pediatr
popul
shown
inhal
tobramycin
effect
erad
p
aeruginosa
although
studi
adult
also
shown
good
efficaci
larg
random
control
trial
requir
recommend
made
indic
use
treatment
pulmonari
exacerb
recent
review
conclud
avail
clinic
data
abl
show
benefit
use
inhal
antibiot
treat
acut
infect
current
use
inhal
tobramycin
treatment
exacerb
also
routin
recommend
evid
need
noncf
bronchiectasi
anoth
indic
inhal
tobramycin
investig
still
limit
data
efficaci
group
patient
prospect
doubleblind
placebocontrol
studi
examin
addit
nebul
tobramycin
oral
ciprofloxacin
compar
oral
ciprofloxacin
alon
signific
differ
group
receiv
ciprofloxacin
alon
group
receiv
combin
nebul
tobramycin
three
studi
shown
reduct
sputum
p
aeruginosa
densiti
improv
lung
function
furthermor
higher
report
advers
effect
includ
cough
dyspnoea
wheez
recent
systemat
review
examin
trial
conclud
use
inhal
antibiot
includ
tobramycin
may
provid
microbiolog
well
clinic
benefit
adult
noncf
bronchiectasi
clinic
stabl
vap
anoth
noncf
pulmonari
diseas
inhal
tobramycin
use
overal
better
evid
use
adjunct
therapi
treatment
compar
use
prophylaxi
use
inhal
antibiot
prophylaxi
also
routin
recommend
approach
lead
emerg
antibiot
resist
clearli
random
control
trial
requir
use
inhal
tobramycin
chronic
obstruct
pulmonari
diseas
copd
also
investig
studi
sever
copd
patient
show
inhal
tobramycin
solut
mg
twice
daili
help
reduc
inflammatori
impact
p
aeruginosa
develop
process
tobramycin
inhal
product
shed
light
formul
issu
need
consid
develop
inhal
product
includ
overcom
inhibitori
effect
sputum
fast
deliveri
reduc
treatment
burden
well
develop
dpi
formul
patient
conveni
antibiot
avail
inhal
product
includ
aztreonam
colistin
offer
treatment
option
potenti
minim
risk
emerg
resist
aztreonam
fig
synthet
monocycl
betalactam
antibiot
inhibit
synthesi
mucopeptid
bacteri
cell
wall
intraven
form
aztreonam
contain
arginin
caus
pulmonari
inflamm
longterm
use
inhal
inhal
product
contain
lysin
well
toler
fda
approv
aztreonam
inhal
product
azli
also
approv
use
europ
unlik
aminoglycosid
antibacteri
activ
aztreonam
significantli
antagon
sputum
cf
patient
administ
pretreat
bronchodil
recommend
due
likelihood
bronchospasm
advers
effect
associ
nebul
therapi
includ
patient
treat
decreas
fev
observ
follow
administr
studi
medic
pretreat
bronchodil
adult
children
year
old
recommend
dose
one
singleus
vial
mg
mix
ampoul
salin
take
approxim
min
inhal
recommend
dosag
regimen
time
day
via
nebulis
system
day
stop
day
follow
repeat
cycl
potenti
advers
effect
includ
headach
chest
discomfort
bronchospasm
throat
discomfort
nasal
congest
cough
fever
tabl
latter
two
commonli
report
children
dose
escal
trial
investig
pharmacokinet
inhal
aztreonam
adult
adolesc
cf
adult
min
inhal
mg
mg
mg
aztreonam
median
sputum
concentr
respect
adolesc
correspond
median
sputum
concentr
furthermor
aztreonam
sputum
concentr
mic
least
h
follow
administr
term
system
exposur
maximum
plasma
concentr
observ
adult
h
inhal
dose
administr
three
time
day
show
better
microbiolog
respons
compar
daili
dose
administ
twice
day
due
fact
predict
pkpd
index
aztreonam
time
mic
rather
c
max
mic
ratio
c
max
mic
area
concentrationtim
curv
auc
mic
ratio
aucmic
random
doubleblind
placebocontrol
multicent
trial
one
cours
day
conduct
cf
patient
moder
sever
lung
diseas
p
aeruginosa
lung
infect
result
show
treatment
significantli
improv
respiratori
symptom
pulmonari
function
compar
placebo
anoth
random
doubleblind
trial
show
median
time
requir
addit
antimicrobi
chemotherapi
prolong
least
day
among
patient
group
compar
patient
without
treatment
openlabel
followon
studi
two
studi
mention
examin
impact
multipl
cours
order
evalu
longterm
safeti
effect
diseas
relat
endpoint
month
ie
nine
treatment
cycl
patient
treatment
reduc
bacteri
densiti
sputum
improv
measur
pulmonari
function
fev
cfqr
respiratori
symptom
score
importantli
treatment
well
toler
cf
patient
also
compar
activecontrol
random
openlabel
multicent
studi
three
cours
treatment
patient
random
either
receiv
mg
three
time
day
mg
twice
daili
demonstr
statist
superior
improv
lung
function
respiratori
symptom
base
upon
cfqr
respiratori
symptom
score
first
treatment
cours
three
treatment
cours
addit
time
requir
intraven
antibiot
administr
prolong
patient
treat
event
rate
week
estim
kaplanmei
method
patient
treat
group
aztreonam
tobramycin
approv
europ
unit
state
unlik
tobramycin
aztreonam
come
form
dri
powder
inhal
still
howev
advantag
shorter
administr
time
compar
tobramycin
inhal
solut
current
phaseiii
trial
carri
investig
continu
altern
therapi
cat
aztreonam
tobramycin
compar
altern
tobramycin
placebo
similar
tobramycin
inhal
aztreonam
also
investig
earli
bacteri
erad
azli
well
toler
effect
erad
p
aeruginosa
pediatr
cf
patient
noncf
bronchiectasi
aztreonam
shown
effect
result
unexpect
aztreonam
show
benefit
cf
patient
pseudomon
infect
unlik
tobramycin
colistin
aztreonam
studi
prevent
vap
treatment
vap
combin
parenter
antibiot
clinic
studi
requir
assess
use
patient
popul
colistin
also
known
polymyxin
e
fig
polypeptid
antibiot
infect
caus
multidrugresist
gramneg
pathogen
commerci
avail
clinic
inact
prodrug
colistimeth
sodium
cm
decad
import
clinician
understand
differ
cm
inact
prodrug
colistin
confus
label
vial
content
differ
cm
product
employ
differ
region
world
like
tobramycin
cm
come
multipl
formul
inhal
nebul
solut
well
dpi
cm
nebul
solut
approv
europ
includ
unit
kingdom
sinc
treatment
respiratori
infect
caus
p
aeruginosa
cf
patient
includ
european
guidelin
inhal
medic
cf
fact
nebul
cm
week
oral
ciprofloxacin
wide
use
cf
patient
sinc
earli
aggress
chemotherapi
p
aeruginosa
detect
sputum
treatment
strategi
significantli
decreas
incid
new
chronic
pseudomon
infect
cf
patient
howev
larg
random
control
studi
nebul
cm
placebocontrol
trial
cf
patient
conduct
nebul
cm
million
intern
unit
twice
day
treatment
period
show
signific
differ
rate
declin
forc
vital
capac
howev
signific
differ
fev
colistintr
placebo
group
studi
compar
nebul
cm
tobramycin
solut
inhal
cf
patient
treatment
cours
demonstr
reduc
bacteri
sputum
densiti
howev
unlik
tobramycin
group
signific
improv
fev
achiev
colistin
group
studi
conduct
unit
kingdom
use
cm
inhal
much
common
inhal
tobramycin
despit
colistin
use
sinc
limit
data
pharmacokinet
cm
colistin
follow
pulmonari
deliveri
recent
pharmacokinet
studi
cm
colistin
follow
intratrach
administr
rat
discov
pulmonari
administr
cm
achiev
high
sustain
exposur
form
colistin
lung
popul
pharmacokinet
analysi
show
high
colistin
concentr
epitheli
line
fluid
elf
due
slow
continu
convers
cm
elf
administr
cm
dose
mgkg
colistin
concentr
elf
sampl
period
maintain
mgl
mic
requir
inhibit
clinic
isol
pharmacokinet
studi
inhal
cm
singl
dose
million
intern
unit
conduct
cf
patient
two
children
hospit
germani
h
administr
cm
pari
star
jet
nebul
maximum
serum
concentr
colistin
ie
polymyxin
around
mgl
patient
serum
concentr
far
lower
previous
report
system
administr
h
mean
concentr
form
colistin
mgl
higher
colistin
mic
breakpoint
p
aeruginosa
propos
british
societi
antimicrobi
chemotherapi
bsac
polymyxin
often
use
lastlin
therapi
gramneg
superbug
clinic
pkpd
studi
urgent
requir
optim
use
inhal
cm
maxim
efficaci
minim
emerg
resist
sinc
steril
powder
cm
also
market
avail
nebul
patient
vial
contain
million
intern
unit
steril
colistimeth
sodium
powder
approxim
equal
mg
colistin
base
activ
cba
ie
mg
chemic
colistimeth
sodium
patient
inhal
dose
depend
sever
infect
type
nebul
use
recommend
dose
adult
children
year
old
chronic
colon
million
intern
unit
ie
mg
cba
inhal
twice
daili
unlik
tobramycin
aztreonam
cm
often
use
continu
patient
chronic
infect
intermitt
common
advers
effect
inhal
cm
ie
patient
includ
cough
bronchospasm
tabl
pilot
studi
show
nebul
colistin
sulfat
well
toler
compar
nebul
cm
cf
patient
receiv
mg
dri
powder
colistin
sulfat
higher
incid
throat
irrit
cough
chest
tight
group
million
intern
unit
nebul
cm
solut
nebul
portaneb
compressor
product
inform
suggest
cm
hydrolys
rapidli
form
colistin
may
caus
pulmonari
toxic
consid
potenti
stabil
issu
cm
nebul
solut
need
use
immedi
reconstitut
even
though
recommend
store
cm
solut
use
recent
stabil
studi
show
cm
reconstitut
ml
water
glucos
infus
solut
salin
concentr
mgml
stabl
colistin
form
least
day
convers
cm
colistin
solut
concentr
temperatur
depend
stabil
data
import
implic
formul
clinic
use
cm
product
numer
investig
examin
dri
powder
inhal
colistin
cm
vitro
particl
engin
studi
show
improv
aerosol
perform
colistin
dri
powder
inhal
great
potenti
reduc
dose
inhal
colistin
even
cm
recent
dpi
formul
colistimeth
sodium
approv
european
medicin
agenc
ema
one
capsul
contain
mg
chemic
cm
equal
approxim
mg
cba
phaseiii
studi
compar
dpi
formul
cm
tobramycin
solut
inhal
mg
ml
week
result
demonstr
effect
noninferior
nebul
tobramycin
adjust
mean
differ
tobramycin
inhal
solut
fev
predict
week
ci
intentiontotreat
popul
n
suscept
test
carri
concentr
colistin
sputum
approxim
time
mic
caus
pathogen
gener
safeti
profil
compar
nebul
tobramycin
group
except
higher
rate
cough
vs
throat
irrit
vs
abnorm
tast
vs
report
group
term
offlabel
use
inhal
cm
noncf
bronchiectasi
limit
inform
literatur
clinic
studi
warrant
random
control
trial
examin
inhal
cm
treatment
vap
adjunct
therapi
show
favor
microbiolog
respons
impact
clinic
outcom
similar
tobramycin
inhal
cm
show
better
result
treatment
vap
compar
prevent
metaanalysi
five
random
control
trial
examin
four
antibiot
includ
colistin
tobramycin
prevent
vap
demonstr
reduct
risk
vap
reduct
mortal
base
current
literatur
inhal
cm
recommend
use
prevent
vap
summari
clinic
pkpd
investig
inhal
cm
requir
optim
treatment
differ
type
respiratori
tract
infect
caus
multidrugresist
gramneg
pathogen
addit
three
aforement
antibiot
inhal
antibiot
product
develop
aradigm
develop
nebul
liposom
formul
ciprofloxacin
fig
complet
phaseiia
clinic
trial
chronic
respiratori
infect
cf
patient
clinic
data
demonstr
signific
declin
bacteri
colon
improv
lung
function
satisfactori
toler
clinic
trial
compris
liposom
free
ciprofloxacin
show
reduc
pulmonari
exacerb
transient
lung
function
declin
noncf
bronchiectasi
patient
compar
pure
liposom
placebo
addit
seem
better
toler
liposom
placebo
noncf
bronchiectasi
patient
bayer
healthcar
recent
complet
phaseii
studi
cf
noncf
bronchiectasi
patient
ciprofloxacin
capsulebas
dpi
form
studi
examin
p
aeruginosa
haemophilu
influenza
oral
inject
form
ciprofloxacin
approv
fda
use
treatment
inhal
anthrax
liposom
ciprofloxacin
current
investig
preclin
stage
prevent
treatment
anthrax
potenti
bioterror
agent
francisella
tularensi
levofloxacin
fig
thirdgener
fluoroquinolon
inhal
formul
investig
phaseiii
studi
levofloxacin
recent
complet
compar
agent
tobramycin
solut
inhal
phaseii
studi
nebul
levofloxacin
well
toler
cf
patient
histori
heavi
exposur
inhal
antibiot
nebul
levofloxacin
treatment
show
signific
clinic
efficaci
reduct
p
aeruginosa
densiti
need
antibiot
treatment
similar
aztreonam
fluoroquinolon
inactiv
sputum
levofloxacin
also
examin
patient
copd
phaseii
studi
although
nebul
levofloxacin
well
toler
signific
clinic
benefit
reduct
exacerb
rate
shown
highrisk
copd
patient
amikacin
fig
liposom
formul
anoth
aminoglycosid
investig
inhal
report
liposom
infiltr
biofilm
therebi
maxim
bacteri
kill
minim
potenti
emerg
resist
furthermor
liposom
formul
slow
releas
drug
may
reduc
dose
frequenc
provid
pkpd
benefit
phaseii
studi
show
mg
daili
dose
improv
lung
function
decreas
sputum
densiti
p
aeruginosa
amikacin
also
use
treat
nontuberculosi
mycobacteria
ntm
cf
patient
nonliposom
amikacin
studi
adjunct
therapi
patient
treatmentrefractori
pulmonari
ntm
diseas
show
improv
clinic
symptom
microbiolog
outcom
unfortun
well
toler
patient
stop
due
advers
effect
ototox
hemoptysi
nephrotox
persist
dysphonia
vertigo
nebul
liposom
formul
current
undergo
phaseii
studi
mycobacterium
avium
abscessu
phaseii
placebo
control
random
studi
investig
nebul
liposom
amikacin
noncf
bronchiectasi
patient
studi
show
inhal
liposom
amikacin
daili
safe
well
toler
patient
receiv
higher
dose
mg
slightli
higher
frequenc
dri
cough
compar
patient
receiv
mg
howev
case
nephrotox
ototox
report
random
control
trial
show
similar
efficaci
nebul
amikacin
intraven
ceftazidim
treatment
vap
caus
p
aeruginosa
nebul
amikacin
effect
even
intermedi
strain
fosfomycin
fig
phosphon
acid
antibiot
activ
gramposit
gramneg
bacteria
combin
tobramycin
activ
p
aeruginosa
also
staphylococcu
aureu
gramposit
pathogen
liquid
formul
combin
fosfomycin
tobramycin
ww
develop
phaseii
trial
recent
complet
phaseii
studi
show
improv
clinic
outcom
reduc
sputum
densiti
bacteri
pathogen
vancomycin
glycopeptid
antibiot
use
treatment
methicillinresist
aureu
mrsa
phaseii
studi
contain
vancomycin
carri
savara
investig
effect
safeti
pharmacokinet
patient
cf
chronic
mrsa
lung
infect
antibiot
investig
inhal
therapi
includ
clindamycin
gentamicin
clarithromycin
telithromycin
describ
even
though
aerosol
antibiot
use
clinic
practic
indic
includ
noncf
bronchiectasi
vap
applic
investig
none
approv
fda
ema
develop
new
antibiot
inhal
product
import
minim
side
effect
eg
sever
cough
throat
irrit
reduc
dose
frequenc
eg
via
control
deliveri
liposom
achiev
faster
deliveri
eg
effici
nebul
dpi
reduc
treatment
burden
patient
achiev
better
complianc
inhal
antibiot
major
approv
formul
undergo
clinic
trial
accept
safeti
profil
howev
oropharyng
irrit
cough
common
advers
event
aqueou
solut
suspens
deliveri
system
dpi
oropharyng
irrit
depend
specif
chemic
natur
mass
drug
deposit
oropharynx
may
allevi
reduc
oropharyng
deposit
drug
particl
engin
design
effici
devic
vitro
character
throat
deposit
becom
critic
highdos
antibiot
tradit
asthma
copd
medic
throat
deposit
aerosol
may
accur
measur
alberta
throat
tradit
usp
induct
port
strategi
reduc
irrit
includ
encapsul
drug
nonirrit
materi
liposom
cough
trigger
inhal
highdos
powder
due
drug
andor
sheer
amount
powder
inhal
rapid
inhal
highli
concentr
solut
dri
powder
may
caus
irrit
chang
osmot
environ
airway
preliminari
clinic
studi
healthi
subject
shown
lower
output
flow
rate
orbit
inhal
may
reduc
event
cough
subject
inhal
dri
powder
mannitol
tabl
summar
data
obtain
number
clinic
studi
incid
cough
event
vari
larg
differ
clinic
trial
due
chemic
natur
drug
differ
subject
condit
healthi
cf
drug
dose
evalu
method
amongst
factor
chemic
natur
drug
appear
influenti
exampl
cf
patient
experienc
lower
incid
cough
vs
control
n
inhal
mg
mannitol
powder
compar
significantli
higher
incid
cough
cf
patient
n
inhal
colistin
methanesulfon
dri
powder
addit
two
studi
examin
differ
inhal
mannitol
cm
demonstr
effect
inhal
design
diminish
therefor
remain
pauciti
inform
compar
common
advers
effect
cough
oropharyng
irrit
inhal
antibiot
futur
studi
warrant
term
formul
dpi
may
alway
first
choic
ventil
patient
patient
hyperreact
airway
prone
cough
particular
true
dose
drug
high
excipi
deposit
lung
use
larg
quantiti
dose
antibiot
need
deliv
lung
inhal
usual
larg
much
higher
dose
inhal
asthma
copd
drug
requir
caus
problem
toler
safeti
exampl
larg
amount
drug
powder
irrit
repeat
irrit
may
lead
inflamm
addit
instantan
increas
osmolar
fluid
respiratori
tract
inhal
caus
irrit
lead
cough
bronchoconstrict
ultim
inflammatori
reaction
therefor
safeti
challeng
consid
highdos
dri
powder
inhal
product
antibiot
develop
infect
principl
hit
hard
hit
fast
well
accept
author
pharmaceut
industri
regard
develop
inhal
antibiot
usual
highest
toler
dose
propos
clinic
trial
order
achiev
clinic
efficaci
acceler
approv
howev
advers
effect
occur
even
approv
inhal
antibiot
due
inhal
highdos
antibiot
henc
dose
strategi
optim
use
antimicrobi
pkpd
superior
clinic
outcom
minim
advers
effect
doubt
pkpd
studi
inhal
antibiot
challeng
human
subject
plasma
pk
may
correl
clinic
efficaci
inhal
treatment
respiratori
infect
bronchoalveolar
lavag
highli
invas
patient
sputum
antibiot
concentr
usual
poor
surrog
drug
exposur
lung
preclin
pkpd
evalu
anim
practic
wide
employ
oral
parenter
administr
antibiot
howev
limit
pkpd
inform
inhal
antibiot
use
anim
model
choic
anim
model
pkpd
studi
antibiot
inhal
usual
base
upon
practic
consider
rodent
rabbit
guinea
pig
commonli
use
larger
anim
speci
factor
includ
welfar
larg
inhal
chamber
consid
addit
safeti
issu
overus
inhal
highdos
antibiot
also
promot
resist
summari
minim
risk
move
new
product
expens
clinic
trial
reliabl
anim
model
requir
determin
predict
pkpd
paramet
inhal
antibiot
inhal
antivir
agent
develop
influenza
viru
coxsacki
viru
echoviru
adenoviru
respiratori
syncyti
viru
rsv
rhinoviru
parainfluenza
viru
corona
viru
recent
human
metapneumoviru
hantaviru
torqu
tenoviru
human
bocaviru
polyomavirus
avian
influenza
viru
polyomaviru
foremost
influenza
viru
main
caus
annual
epidem
rsv
parainfluenza
viru
commonli
respons
viral
infect
lower
respiratori
tract
children
rhinovirus
caus
approxim
common
cold
viral
pharyng
tonsil
commonli
caus
adenovirus
infect
wherea
croup
commonli
associ
parainfluenza
viru
infect
clearli
complex
etiolog
pathogenesi
respiratori
viral
infect
repres
seriou
threat
human
health
immin
emerg
respiratori
virus
unknown
epidemiolog
signific
also
worrisom
section
cover
current
avail
inhal
antivir
agent
includ
safeti
efficaci
aforement
human
respiratori
virus
ribavirin
fig
nebul
solut
mgml
broadspectrum
antivir
synthet
purin
nucleosid
analogu
current
approv
treatment
rsv
highrisk
infant
lassa
fever
viru
hepat
c
viru
conjunct
pegyl
interferon
ribavirin
prodrug
metabol
activ
form
resembl
purin
guanosin
nucleotid
due
structur
similar
guanosin
ribavirin
interfer
viral
replic
incorpor
viral
transcript
lead
errorpron
replic
rna
virus
ribavirin
also
interfer
guanosin
synthesi
viral
mrna
cap
ribavirin
administ
smallparticl
aerosol
via
mask
tent
mechan
ventil
h
daili
day
expens
ribavirin
deliveri
aerosol
h
daili
inconveni
aerosol
ribavirin
therapi
larg
restrict
highrisk
patient
includ
prematur
birth
organ
transplant
recipi
chronic
lung
diseas
congenit
heart
diseas
immunodefici
diseas
inhal
ribavirin
therapi
also
success
use
treatment
parainfluenza
viru
respiratori
tract
infect
infant
sever
immunodefici
notabl
inhal
ribavirin
combin
intraven
immunoglobulin
e
show
good
efficaci
treatment
adult
blood
marrow
transplant
recipi
aerosol
ribavirin
well
toler
infant
adult
advers
effect
minim
poorli
absorb
system
caus
hemolyt
anemia
observ
oral
administr
pediatr
patient
receiv
ribavirin
administ
face
mask
hday
day
plasma
concentr
rang
mean
concentr
plasma
halflif
h
infrequ
bronchospasm
sudden
deterior
respiratori
function
report
infant
receiv
aerosol
ribavirin
accordingli
respiratori
function
must
close
monitor
therapi
termin
immedi
first
sign
respiratori
distress
view
ribavirin
embryotox
teratogen
sever
anim
speci
precaut
taken
avoid
drug
exposur
pregnant
healthcar
worker
tend
patient
receiv
aerosol
ribavirin
therapi
anim
influenza
infect
model
inhal
ribavirin
deliv
via
nebul
show
protect
lethal
challeng
influenza
viru
control
human
clinic
trial
administr
aerosol
ribavirin
therapi
within
h
onset
ill
produc
signific
reduct
sever
ill
compar
placebo
group
irrespect
preliminari
result
ribavirin
approv
treatment
influenza
infect
patient
major
safeti
concern
applic
influenza
therapi
includ
hemolyt
anemia
tabl
teratogen
commonli
associ
intraven
administr
ribavirin
clearli
clinic
trial
warrant
assess
safeti
efficaci
aerosol
ribavirin
influenza
therapi
ribavirin
also
trial
treatment
hantaviru
infect
caus
hemorrhag
fever
renal
syndrom
hantaviru
pulmonari
syndrom
human
mix
find
report
clinic
evalu
need
zanamivir
fig
nacetylneuramin
acid
sialic
acid
transit
state
analogu
inhibit
influenza
viral
neuraminidas
block
releas
progeni
viru
particl
infect
cell
therebi
halt
replic
cycl
high
degre
homolog
among
neuraminidas
activ
site
influenza
b
strain
endow
compound
broad
spectrum
activ
current
circul
influenza
strain
mutat
neuraminidas
gene
andor
hemagglutinin
gene
influenza
virus
associ
resist
neuraminidas
inhibitor
world
health
organ
collabor
center
surveil
studi
detect
zanamivir
resist
season
influenza
isol
neuraminidas
mutat
one
common
resist
phenotyp
observ
across
influenza
virus
subtyp
mutat
associ
high
level
viral
resist
oseltamivir
wherea
zanamivir
laninamivir
octano
see
section
remain
activ
viral
resist
zanamivir
found
correl
mutat
neuraminidas
inhal
neuraminidas
inhibitor
play
extrem
import
role
improv
surviv
outcom
season
pandem
influenza
treatment
antivir
drug
prove
particularli
import
reduc
durat
ill
sever
influenza
infect
sever
case
rate
influenzarel
complic
highrisk
patient
eg
elderli
zanamivir
glaxosmithklin
poor
oral
bioavail
ideal
suit
administr
aerosol
inhal
zanamivir
deliv
dri
powder
diskhal
inhal
devic
one
blister
inhal
treatment
begin
within
h
onset
symptom
recommend
dose
treatment
influenza
infect
children
age
year
adult
two
inhal
mg
twice
daili
five
day
total
daili
inhal
dose
mg
recommend
dose
postexposur
prophylaxi
within
h
exposur
infect
individu
two
inhal
mg
daili
day
recommend
dose
season
prophylaxi
commun
outbreak
two
inhal
mg
daili
day
inhal
approxim
dri
powder
deposit
lower
respiratori
tract
remaind
oropharynx
remain
h
treatment
initi
soon
possibl
follow
symptom
onset
ideal
within
h
clinic
trial
shown
adher
treatment
window
significantli
reduc
durat
ill
symptom
sever
rate
influenza
associ
complic
compar
studi
shown
treatment
inhal
zanamivir
effect
oral
oseltamivir
reduc
symptom
sever
patient
infect
either
influenza
b
virus
random
placebocontrol
studi
also
convincingli
demonstr
zanamivir
efficaci
use
prophylaxi
howev
yet
approv
indic
combin
use
oral
oseltamivir
inhal
zanamivir
antivir
treatment
proven
use
prevent
influenzarel
complic
ventil
extracorpor
membran
oxygen
ecmo
treat
critic
ill
patient
infect
pandem
influenza
zanamivir
gener
well
toler
patient
side
effect
report
howev
direct
powder
inhal
shown
exacerb
respiratori
distress
decreas
pulmonari
function
caus
cough
potenti
fatal
bronchospasm
patient
asthma
chronic
obstruct
pulmonari
diseas
tabl
fact
death
caus
offlabel
use
relenza
ie
powder
formul
reconstitut
liquid
nebul
due
blockag
expiratori
filter
presum
lactos
formul
incid
might
avoid
relenza
use
via
diskhal
dpi
feasibl
intub
patient
use
ambubag
deliveri
system
nevertheless
use
zanamivir
prohibit
patient
compromis
respiratori
function
laninamivir
fig
longact
version
zanamivir
laninamivir
octano
daiichi
sankyo
japan
inhal
neuraminidas
inhibitor
approv
japan
treatment
prophylaxi
influenza
b
viru
infect
adult
children
laninamivir
octano
octanoyl
ester
prodrug
transform
via
convers
activ
form
laninamivir
intracellular
esteras
follow
uptak
epitheli
cell
line
airway
activ
laninamivir
retain
airway
concentr
higher
ic
influenza
neuraminidas
day
follow
singl
inhal
dose
mg
although
effici
safeti
laninamivir
octano
compar
zanamivir
oncedaili
dose
mg
adult
mg
children
year
age
dri
powder
inhal
make
laninamivir
octano
therapi
conveni
prolong
high
exposur
laninamivir
respiratori
tissu
believ
due
limit
efflux
epitheli
cell
laninamivir
display
compar
activ
oseltamivir
current
circul
influenza
b
virus
includ
virus
carri
neuraminidas
mutat
inhal
laninamivir
octano
well
toler
notabl
compar
rate
nausea
vomit
observ
patient
treat
laninamivir
octano
tabl
treat
oseltamivir
recent
phaseii
clinic
trial
refer
igloo
conduct
biota
pharmaceut
compar
safeti
efficaci
mg
mg
dose
laninamivir
octano
lani
deliv
inhal
disappointingli
allevi
patientreport
influenza
symptom
compar
placebo
although
statist
signific
reduct
viral
shed
shown
patient
dose
day
interferon
ifn
human
glycoprotein
interfer
viral
infect
trigger
intracellular
product
antivir
protein
broad
antivir
activ
interferon
make
consider
util
resolut
prophylaxi
respiratori
viral
infect
includ
rhinoviru
influenza
b
parainfluenza
adenoviru
coronaviru
advanc
recombin
protein
express
purif
technolog
enabl
routin
product
larg
amount
purifi
human
interferon
protein
rel
low
cost
intranas
interferon
effect
prevent
rhinoviru
cold
via
postexposur
prophylaxi
famili
contact
howev
proven
effect
treatment
establish
infect
intranas
dose
intern
unit
iu
twice
daili
week
provid
approxim
protect
rhinoviru
respiratori
infect
respons
common
cold
degre
protect
depend
upon
interferon
dose
durat
use
prior
viru
exposur
high
dose
iu
per
day
prevent
infect
wherea
infect
observ
lower
dose
iu
per
day
notabl
prophylact
low
dose
approxim
iu
per
day
shown
effect
prevent
infect
begun
week
prior
viru
exposur
protect
also
demonstr
infect
caus
coronaviru
second
common
etiolog
cold
partial
protect
demonstr
experiment
influenza
viru
infect
util
treatment
respiratori
infect
highrisk
patient
yet
comprehens
investig
major
sideeffect
associ
interferon
intranas
spray
irrit
local
nasal
symptom
includ
nasal
obstruct
nasal
dryness
bleed
bloodting
nasal
mucu
nasal
stuffi
ulcer
eros
tabl
sever
symptom
depend
upon
dose
durat
treatment
approxim
volunt
receiv
iu
per
intranas
interferon
daili
report
experienc
symptom
system
toxic
transient
leukopenia
note
larg
dose
iuday
interferon
nasal
spray
week
use
pfizer
develop
potenti
intranas
therapeut
rupintrivir
fig
syn
small
molecul
inhibitor
human
rhinoviru
proteas
random
doubleblind
placebocontrol
phaseii
studi
involv
healthi
volunt
treatment
suspens
rupintrivir
via
intranas
deliveri
produc
reduct
viral
titer
individu
symptom
score
nasal
discharg
weight
rupintrivir
well
toler
anim
human
test
subject
howev
subject
report
bloodting
mucu
subject
report
nasal
passag
irrit
number
pharmaceut
compani
develop
small
molecul
rsv
fusionentri
inhibitor
great
potenti
clinic
develop
potenti
suit
formul
aerosol
deliveri
fig
wyethayerst
potent
analog
origin
lead
compound
show
good
efficaci
follow
intranas
administr
mous
african
green
monkey
model
rsv
infect
dose
low
mgkg
fig
syn
experiment
rsv
fusion
inhibitor
licens
viropharma
microdos
therapeutx
develop
dri
powder
formul
inhal
deliveri
report
johnson
johnson
develop
inhal
rsv
fusion
inhibitor
jnj
compound
show
good
antirsv
efficaci
safeti
rat
rsv
infect
model
efficaci
dose
mgkg
day
fig
anoth
small
molecul
rsv
fusion
inhibitor
develop
johnson
johnson
intraven
administr
mgkg
rat
display
prophylact
protect
effect
treatment
rsv
challeng
within
time
window
bristolmy
squibb
develop
advanc
lead
rsv
fusion
inhibitor
show
good
oral
avail
low
cytotox
ec
high
antirsv
activ
ec
nm
poli
iclc
potent
immunostimulatori
antivir
compound
consist
synthet
doubl
strand
polyriboinosinicpolyribocytidyl
c
acid
stabil
polyllysin
carboxymethylcellulos
intranas
liposomeencapsul
poli
iclc
mgkgdose
display
broadspectrum
activ
robust
protect
mice
lethal
challeng
number
season
influenza
virus
includ
highli
pathogen
avian
influenza
viru
poli
iclc
elicit
antivir
immun
respons
via
activ
tolllik
induc
product
turn
lead
stimul
innat
adapt
immun
respons
includ
activ
natur
killer
cell
develop
effort
current
focus
product
nasal
spray
deliv
effect
dose
poli
iclc
directli
respiratori
tract
nanotherapeut
award
million
nation
institut
allergi
infecti
diseas
niaid
year
contract
develop
inhal
formul
inject
antivir
drug
cidofovir
postexposur
prophylaxi
treatment
smallpox
viru
variola
major
develop
inhal
antivir
treatment
certainli
viabl
develop
strategi
consid
transmiss
smallpox
viru
occur
inhal
airborn
viru
develop
inhal
cidofovir
therapeut
also
provid
prophylaxi
individu
current
approv
smallpox
vaccin
contraind
suffer
sever
exfoli
skin
diseas
immunocompromis
pregnanc
success
complet
excit
program
yield
practic
costeffect
treatment
solut
deadli
categori
bioterror
agent
summari
respiratori
virus
major
caus
morbid
mortal
human
popul
inhal
antivir
provid
signific
pharmacokineticspharmacodynam
benefit
essenti
maxim
efficaci
minim
potenti
system
toxic
emerg
resist
current
hand
approv
inhal
antivir
drug
increas
incid
resist
emerg
new
respiratori
virus
concern
use
inhal
antivir
agent
differ
mode
action
combin
may
one
best
mean
wherebi
emerg
resist
avoid
anoth
barrier
optim
use
inhal
antivir
delay
viral
diagnosi
new
improv
inhal
antivir
agent
approv
rapid
viral
diagnosi
play
major
role
optim
use
chemoprophylaxi
treatment
respiratori
viral
infect
fungal
pulmonari
infect
major
caus
mortal
transplant
patient
aid
due
toxic
associ
system
administ
antifung
agent
inhal
deliveri
attract
altern
clinic
understand
inhal
antifung
agent
come
aerosol
amphotericin
b
formul
pneumocysti
pneumonia
pcp
common
caus
pneumonia
patient
aid
high
mortal
inhal
pentamidin
fig
antifung
approv
prophylaxi
pcp
caus
pneumocysti
jirovecii
formerli
known
p
carinii
number
studi
shown
inhal
pentamidin
therapi
effect
indic
albeit
applic
reserv
patient
toler
firstlin
therapi
trimethoprimsulfamethoxazol
dapson
recommend
dose
aerosol
pentamidin
isethion
adult
mg
everi
week
use
respirgard
nebul
deliveri
min
sideeffect
tabl
includ
cough
throat
irrit
bronchospasm
fatigu
dizzi
major
concern
pentamidin
inhal
therapi
secondari
infect
may
aris
due
herp
zoster
oral
candida
influenza
aerosol
formul
amphotericin
b
fig
polyen
antifung
use
treatment
pulmonari
aspergillosi
infect
aid
lung
transplant
patient
amphotericin
b
avail
two
differ
form
deoxychol
liposom
form
type
deliveri
devic
togeth
variabl
particl
size
aerosol
amphotericin
b
formul
shown
impact
upon
halflif
pulmonari
distribut
singl
dose
nebul
liposom
amphotericin
b
display
prolong
antifung
activ
longer
halfliv
rodent
patient
compar
deoxychol
formul
term
prophylaxi
efficaci
clinic
trial
aerosol
liposom
amphotericin
b
lung
transplant
recipi
show
administr
everi
week
may
suffici
prevent
aspergillosi
infect
without
advers
effect
although
sever
studi
patient
lung
transplant
hematolog
malign
report
promis
result
due
mix
find
small
patient
number
involv
use
inhal
amphotericin
b
prophylaxi
aspergillu
infect
current
recommend
inhal
amphotericin
b
combin
also
success
trial
treatment
postinfluenza
pseudomembran
necrotis
bronchial
aspergillosi
infect
number
studi
evalu
intrapulmonari
pharmacokinet
variou
formul
amphotericin
b
use
differ
nebul
nebul
amphotericin
b
deoxychol
use
respirgard
devic
gener
particl
deposit
upper
lower
respiratori
tract
sideeffect
associ
aerosol
amphotericin
b
includ
cough
tongu
numb
tast
disturb
chest
tight
nausea
vomit
tabl
voriconazol
fig
broadspectrum
antifung
current
avail
intraven
infus
cyclodextrin
ligand
pharmaceut
aerosol
intraven
formul
demonstr
effect
target
airway
deliveri
pulmonari
aspergillosi
caus
fumig
anim
infect
model
patient
notabl
inhal
voriconazol
substanti
concentr
lung
show
good
safeti
rodent
infect
model
taken
togeth
encourag
preliminari
find
advoc
need
clinic
studi
effect
antifung
agent
fig
merck
water
solubl
lipopeptid
shown
effect
antipneumocysti
agent
rat
model
p
jirovecii
pneumonia
infect
rat
aerosol
administ
daili
dose
effect
prevent
develop
cyst
pneumonia
ideal
develop
aerosol
prophylact
p
jirovecii
pneumonia
aerosol
nanostructur
intraconazol
effect
prophylaxi
invas
pulmonari
aspergillosi
mous
infect
model
aerosol
caspofungin
also
shown
decreas
mortal
pulmonari
aspergillosi
rat
administ
prophylact
compar
inhal
antivir
antibacteri
agent
pauciti
studi
safeti
pharmacokinet
efficaci
inhal
antifung
agent
vivo
studi
urgent
requir
elucid
role
inhal
antifung
agent
treatment
pulmonari
fungal
infect
wider
varieti
diseas
state
avail
inhal
antifung
simpli
aerosol
form
intraven
formul
drug
antifung
drug
specif
design
formul
includ
dri
powder
inhal
product
sever
lack
although
promis
antifung
compound
specif
formul
aerosol
pipelin
pharmaceut
sector
need
invest
heavili
neglect
area
lack
therapeut
option
respiratori
infect
caus
emerg
microbi
pathogen
repres
major
threat
human
health
worldwid
review
underscor
import
inhal
deliveri
antiinfect
combat
human
respiratori
infect
respons
million
death
year
notwithstand
associ
econom
burden
main
advantag
inhal
use
antiinfect
afford
high
drug
exposur
primari
site
infect
minim
risk
potenti
system
toxic
avoid
unfavor
pkpd
associ
system
use
therapeut
valu
inhal
antiinfect
agent
depend
upon
sever
frequenc
infect
safeti
pkpd
antiinfect
agent
particularli
criticallyil
patient
highest
risk
complic
new
product
administ
inhal
rout
must
safe
accept
toler
detail
herein
number
promis
inhal
antiinfect
drug
candid
current
development
pipelin
found
safe
repres
valuabl
therapeut
option
clinician
improv
outcom
surviv
rate
patient
difficulttotreat
respiratori
infect
